The longevity and efficiency of Invivofectamine® 3.0 as a means to deliver nucleic acid for developing treatments for Age-Related Macular Degeneration
Researchers
- Associate Professor Riccardo Natoli Natoli (Primary Investigator)
- Dr Joshua Chu-Tan (Secondary Investigator)
- Professor Jan Provis (Secondary Investigator)
- Dr Matt Rutar (Secondary Investigator)
- Mr Kartik Saxena (Secondary Investigator)
Grant status
CompletedGrant start date
06/11/2015Grant funding
- 2015: $7,270 from Thermo Fisher Scientific Inc
